Bill > HR4184

This bill amends the Internal Revenue Code to create a new tax provision that excludes certain payments received by clinical trial participants from gross income. Specifically, the bill establishes that individuals will not have to pay taxes on compensation received for participating in an "approved clinical trial" or for reimbursing expenses related to their participation. An approved clinical trial is defined using language from the Public Health Service Act, broadly covering trials for various diseases or conditions. The bill defines these payments as "qualified clinical trial payments" and clarifies that "dependent" has the same meaning as in existing tax code section 152. Additionally, the bill ensures that these clinical trial payments will not be counted as income or resources when determining an individual's eligibility for federal, state, or local assistance programs. The tax exclusion will take effect for amounts paid after December 31, 2025, providing a future implementation date that gives government agencies and organizations time to prepare for the new regulation. This legislation aims to remove potential financial barriers that might discourage individuals from participating in important medical research by ensuring that compensation for clinical trials does not negatively impact their tax liability or benefits eligibility.

Budget and Finance

https://www.congress.gov/bill/119th-congress/house-bill/4184/all-info